Last reviewed · How we verify
nitrofurantoin monohydrate/macrocrystalline capsules
nitrofurantoin monohydrate/macrocrystalline capsules is a Nitrofuran antibiotic Small molecule drug developed by University of California, San Diego. It is currently FDA-approved for Uncomplicated urinary tract infections (acute cystitis), Chronic suppressive therapy for recurrent urinary tract infections. Also known as: Macrobid.
Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA and proteins, leading to cell death.
Nitrofurantoin is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA and proteins, leading to cell death. Used for Uncomplicated urinary tract infections (acute cystitis), Chronic suppressive therapy for recurrent urinary tract infections.
At a glance
| Generic name | nitrofurantoin monohydrate/macrocrystalline capsules |
|---|---|
| Also known as | Macrobid |
| Sponsor | University of California, San Diego |
| Drug class | Nitrofuran antibiotic |
| Target | Bacterial DNA and ribosomal proteins (non-specific after activation) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Nitrofurantoin is a prodrug that requires bacterial nitroreductase enzymes to be converted into highly reactive intermediates. These intermediates cause strand breaks in bacterial DNA and damage to ribosomal proteins and other essential cellular components. This multi-target mechanism makes resistance development less likely and provides broad-spectrum activity against many urinary tract pathogens.
Approved indications
- Uncomplicated urinary tract infections (acute cystitis)
- Chronic suppressive therapy for recurrent urinary tract infections
Common side effects
- Nausea
- Headache
- Diarrhea
- Peripheral neuropathy (with prolonged use)
- Pulmonary toxicity (rare)
- Hepatotoxicity (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nitrofurantoin monohydrate/macrocrystalline capsules CI brief — competitive landscape report
- nitrofurantoin monohydrate/macrocrystalline capsules updates RSS · CI watch RSS
- University of California, San Diego portfolio CI
Frequently asked questions about nitrofurantoin monohydrate/macrocrystalline capsules
What is nitrofurantoin monohydrate/macrocrystalline capsules?
How does nitrofurantoin monohydrate/macrocrystalline capsules work?
What is nitrofurantoin monohydrate/macrocrystalline capsules used for?
Who makes nitrofurantoin monohydrate/macrocrystalline capsules?
Is nitrofurantoin monohydrate/macrocrystalline capsules also known as anything else?
What drug class is nitrofurantoin monohydrate/macrocrystalline capsules in?
What development phase is nitrofurantoin monohydrate/macrocrystalline capsules in?
What are the side effects of nitrofurantoin monohydrate/macrocrystalline capsules?
What does nitrofurantoin monohydrate/macrocrystalline capsules target?
Related
- Drug class: All Nitrofuran antibiotic drugs
- Target: All drugs targeting Bacterial DNA and ribosomal proteins (non-specific after activation)
- Manufacturer: University of California, San Diego — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Uncomplicated urinary tract infections (acute cystitis)
- Indication: Drugs for Chronic suppressive therapy for recurrent urinary tract infections
- Also known as: Macrobid
- Compare: nitrofurantoin monohydrate/macrocrystalline capsules vs similar drugs
- Pricing: nitrofurantoin monohydrate/macrocrystalline capsules cost, discount & access